The Phase II clinical trial of ixazumib, the first oral proteasome inhibitor in MM
Can venetoclax be used to treat multiple myeloma (MM)?
Changing the strategy: early treatment for improved survival in MM
Developments in therapies for AML - chemotherapy, targeted therapy and immunotherapy
Hagop M. Kantarjian
Transforming healthcare with Twitter: A physician’s perspective